|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoamine_oxidase_inhibitor
|
|
gptkbp:ATCCode
|
gptkb:N06AF03
|
|
gptkbp:brand
|
gptkb:Nardil
|
|
gptkbp:CASNumber
|
51-71-6
|
|
gptkbp:color
|
white to off-white powder
|
|
gptkbp:contraindication
|
gptkb:liver_disease
gptkb:pheochromocytoma
congestive heart failure
use with SSRIs
use with other MAOIs
|
|
gptkbp:discoveredBy
|
gptkb:Parke-Davis
|
|
gptkbp:drugClass
|
gptkb:antidepressant
gptkb:benzodiazepine
|
|
gptkbp:eliminationHalfLife
|
11.6 hours
|
|
gptkbp:excretion
|
urine
|
|
gptkbp:hasMolecularFormula
|
C8H12N2
|
|
gptkbp:introducedIn
|
1961
|
|
gptkbp:IUPACName
|
gptkb:2-phenylethylhydrazine
|
|
gptkbp:KEGGID
|
D08367
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
irreversible inhibition of monoamine oxidase
|
|
gptkbp:MeSH_ID
|
D010618
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:pregnancyCategory
|
C (US)
|
|
gptkbp:proteinBinding
|
gptkb:unknown
|
|
gptkbp:PubChem_CID
|
4761
4597
CHEMBL1407
DB00780
|
|
gptkbp:riskFactor
|
gptkb:serotonin_syndrome
hypertensive crisis with tyramine
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gptkb:orthostatic_hypotension
gptkb:sexual_dysfunction
dizziness
weight gain
insomnia
dry mouth
|
|
gptkbp:solubility
|
soluble in water
|
|
gptkbp:storage
|
protect from light
|
|
gptkbp:synonym
|
gptkb:Nardil
gptkb:phenylethylhydrazine
|
|
gptkbp:UNII
|
9J12GAI3OG
|
|
gptkbp:usedFor
|
gptkb:depression
gptkb:panic_disorder
anxiety disorders
|
|
gptkbp:bfsParent
|
gptkb:Antidepressants
|
|
gptkbp:bfsLayer
|
6
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Phenelzine
|